High dose IL-2 in the treatment of metastatic melanoma and metastatic renal cell carcinoma.

被引：0
|
作者：
Woodrum, T [1 ]
机构：
[1] Nebraska Med Ctr, Omaha, NE USA
来源：
ONCOLOGY NURSING FORUM | 2004年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
86
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [41] High-dose interleukin-2 (HD IL-2) for metastatic renal Cell carcinoma (mRCC): Contemporary utilization trends in the United States
    Allard, Christopher B.
    Gelpi-Hammerschmidt, Francisco
    Harshman, Lauren Christine
    Faiena, Izak
    Modi, Parth K.
    Chung, Benjamin I.
    Singer, Eric A.
    Chang, Steven L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [42] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Ajjai Alva
    Gregory A. Daniels
    Michael K. K. Wong
    Howard L. Kaufman
    Michael A. Morse
    David F. McDermott
    Joseph I. Clark
    Sanjiv S. Agarwala
    Gerald Miletello
    Theodore F. Logan
    Ralph J. Hauke
    Brendan Curti
    John M. Kirkwood
    Rene Gonzalez
    Asim Amin
    Mayer Fishman
    Neeraj Agarwal
    James N. Lowder
    Hong Hua
    Sandra Aung
    Janice P. Dutcher
    Cancer Immunology, Immunotherapy, 2016, 65 : 1533 - 1544
  • [43] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Alva, Ajjai
    Daniels, Gregory A.
    Wong, Michael K. K.
    Kaufman, Howard L.
    Morse, Michael A.
    McDermott, David F.
    Clark, Joseph I.
    Agarwala, Sanjiv S.
    Miletello, Gerald
    Logan, Theodore F.
    Hauke, Ralph J.
    Curti, Brendan
    Kirkwood, John M.
    Gonzalez, Rene
    Amin, Asim
    Fishman, Mayer
    Agarwal, Neeraj
    Lowder, James N.
    Hua, Hong
    Aung, Sandra
    Dutcher, Janice P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (12) : 1533 - 1544
  • [44] Predicting response to IL-2 therapy for metastatic melanoma
    Guminski, Alexander D.
    Thompson, John F.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (11) : 1571 - 1575
  • [45] High-dose interleukin-2 in metastatic renal cell carcinoma
    Fernández-Rodríguez, R
    de Argumedo, GL
    Mañé, JM
    Muñoz, A
    Ferreiro, J
    Fuente, N
    López-Vivanco, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6797 - 6798
  • [46] Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma
    Clark, James M.
    Kelley, Benjamin
    Titze, Jill
    Fung, Henry
    Maciejewski, John
    Nathan, Sunita
    Rich, Elizabeth
    Basu, Sanjib
    Kaufman, Howard L.
    ONCOLOGY, 2013, 84 (02) : 123 - 126
  • [47] Outcome predictors in patients receiving high-dose interleakin-2 therapy for the treatment of metastatic melanoma and renal cell carcinoma
    Whyman, Jeremy D.
    Hitchcock, Whitney
    James, Spencer L.
    Shatzel, Joseph J.
    Ernstoff, Marc S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM)
    Stebbing, J
    Benson, C
    Eisen, T
    Mak, I
    Pyle, L
    Smalley, K
    Gore, ME
    BRITISH JOURNAL OF CANCER, 2000, 83 : 31 - 31
  • [49] Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma
    Chu, Melinda Bernabe
    Fesler, Mark
    Armbrecht, Eric
    Fosko, Scott
    Hsueh, Eddy C.
    Richart, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)
    Huland, E
    Heinzer, H
    Huland, H
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2679 - 2683
12345